Zydus Lifesciences gets exclusive marketing rights for innovative prognostic test ‘CanAssist Breast’

16 Nov 2022 Evaluate

Zydus Lifesciences has received exclusive marketing rights for CanAssist Breast- an innovative prognostic test for breast cancer patients. CanAssist Breast is a test to optimize treatment selection in early stage (I & II) hormone receptor positive, HER2 receptor negative type of breast cancer. It determines the patient’s risk of breast cancer recurrence and classifies patient as ‘low risk’ or ‘high risk’ using proprietary Artificial Intelligence/ Machine Learning methods. CanAssist Breast spares patients of physiological toxicity and is also patient-centric in terms of affordability as it is being made available at 80 percent lesser than the cost of global tests.

Zydus Lifesciences (formerly known as Cadila Healthcare) is an India-based pharmaceutical company.

Zydus Lifesciences Share Price

906.00 -10.55 (-1.15%)
13-Mar-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1800.50
Dr. Reddys Lab 1293.00
Cipla 1314.10
Zydus Lifesciences 906.00
Lupin 2314.85
View more..
Register Now to get our Free Newsletter & much more!

© 2026 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×